CGEN Compugen Ltd

XNAS 2.50 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

CGEN $2.50 —
Key stats
$2.50
52-Week Range
$1.43 – $3.23
YTD
+61.29%
Straddle Price
$0.60
P/C Vol Ratio
1.96
Market Cap
$0.2B
Open
$1.97
Day Range
$1.84 – $2.00
Volume
251,045
Prev Close
$1.96
Fair Value
+50.0% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.12%
Beta vs SPY1.43
Cost of Equity (CAPM)12.98% (VRP-adj)
WACC12.87%
Volatility Risk Premium+182.7pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Book / Price55.9% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$2.17 (Market Anchor value)
SMA 20 / Bollinger Mid$2.01
Bollinger Width / SMA2013.7% (drives anchor stability)
Net Debt$-0.1B
Market Cap$0B
Peers used for multiples: DRTS, FROG, MDWD, NEXN, NVMI, PLTK (filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$4.03
Deviation
+50.0%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B $14.20 16% median 13.0× · 3 peers
Peer P/S n/a 0% median 27.0× · 4 peers
Market Anchor (SMA50) $2.17 84% stability 82% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-11-19 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.2B
Employees
75
List Date
2000-08-11
CIK
0001119774
Last Earnings
Nov 9 before open · +9.2% vs ±131.1% expected
Next Earnings
~Mar 1, 2027 (estimated)
Homepage
https://www.cgen.com

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximu…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart

Markers: Click a marker type to show or hide it. Earnings turn amber when the stock moved more than options implied; hollow markers are still to come, or insider trades under a 10b5-1 plan. Intraday times are New York time; shaded bars are pre-market and after-hours.

Seasonality
Month'21'22'23'24'25'26Avg
Jan-4.70%-23.49%22.37%20.80%41.21%18.71%12.48%
Feb-28.45%-13.69%-9.17%6.61%-16.52%0.00%-10.20%
Mar-13.84%1.58%-13.76%-2.27%-19.34%-5.33%-8.83%
Apr-1.71%-27.88%-11.94%-21.86%13.48%20.91%-4.83%
May-7.19%-20.60%80.50%9.05%-3.29%-2.95%9.25%
Jun7.67%2.78%10.68%-23.29%18.67%-13.01%0.58%
Jul-15.12%-16.15%0.87%1.14%-16.18%10.07%-5.89%
Aug5.25%-26.42%-4.20%15.38%-4.73%7.56%-1.19%
Sep-14.84%-42.87%-18.42%-5.73%2.80%-8.11%-14.53%
Oct8.71%35.82%-20.83%-13.51%10.62%-15.38%0.91%
Nov-33.63%15.38%-12.80%-7.02%-9.83%-4.04%*-8.66%
Dec-0.46%-36.66%182.45%2.00%1.32%--29.73%
Total-68.47%-86.19%159.22%-25.76%2.74%1.34%-2.85%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $2.01
SMA 50: $2.16
SMA 200: $2.30
Current: $1.89
EMA 12: $2.01
EMA 26: $2.05
MACD: -0.0389 | Signal: 0.0000
BEARISH
ADX (14): 15.36
RANGE
+DI: 16.75
−DI: 30.78

Momentum Oscillators

RSI (14): 37.83
NEUTRAL
Stoch %K: 34.08
Stoch %D: 49.96
Williams %R: -85.48

Volume & Volatility

BB Upper: $2.15
BB Lower: $1.86
NEUTRAL
OBV: 18,200,450
Vol SMA 20: 208,765
Vol ROC: -16.48%
ATR: $0.10
True Range: $0.16
HV 20: 52.7%
HV 30: 60.2%
HV 60: 49.3%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-11-20T00:00:00 – 2026-11-18T00:00:00
AI Analysis
Written before CGEN’s Nov 9 earnings report, so it doesn’t reflect the results.

LLM Stock Analysis Report

SYMBOL: CGEN CURRENT PRICE: $2.76

Executive Summary Overall Assessment: NEUTRAL (confidence level: 6/10) Key Drivers: + Bullish MACD signal with a high degree of volatility, indicating potential for increased momentum. + Neutral RSI reading, suggesting the stock is not overbought or oversold. + High beta and volatility, making it more susceptible to market movements.

Primary Risks: + High risk due to high beta and volatility. + News sentiment may contradict technical signals, highlighting the need for careful analysis.

Investment Thesis: The stock has shown significant volatility, with recent price movements driven by various news headlines. While the MACD signal is bullish, the RSI reading suggests a neutral market. The high beta indicates a higher risk profile, making it essential to carefully assess potential catalysts and risks before making an investment decision.

Recent News Sentiment Impact: The recent news headlines are mostly neutral, with no significant positive or negative sentiment detected. However, this neutrality could be influenced by the upcoming earnings report, which may impact the stock's price movement.

Technical Analysis

Trend Direction: Short-term (1-4 weeks): Uptrend Medium-term (1-3 months): Neutral Long-term (3-12 months): Downtrend

Support/Resistance Levels: Upper Bollinger Band: $2.98 Middle Bollinger Band: $2.76 Lower Bollinger Band: $2.55

Momentum Signals: RSI Interpretation: Neutral (51.33) MACD Signal: Bullish (0.03 / -0.03 / 0.06) Bollinger Bands Position: Neutral

Volume Analysis: Volume SMA 20: 545953.55 On-Balance Volume (OBV): 16985979.25 Volume Rate of Change: 12.73%

News & Sentiment Analysis

Recent Headlines Summary: The recent news headlines are mostly neutral, with no significant positive or negative sentiment detected.

Sentiment Assessment: Neutral

Catalyst Identification: None identified

Market Narrative: The market narrative is currently driven by the stock's high volatility and beta, making it more susceptible to price movements. The recent news headlines have not had a significant impact on the stock's price movement.

Risk & Volatility Assessment

Beta Interpretation: High risk relative to the market (beta >1.5)

Volatility Regime: High volatility

Options Market Signals: IV Rank: 41.4% (Medium) Current IV: 203.7% Expected Move: $0.35 (22 DTE), 7-DTE: $0.35 Volume Flow: 22 calls vs 73 puts Open Interest: 1,996 calls vs 507 puts Put/Call Volume Ratio: 3.32 (Bearish sentiment) Put/Call OI Ratio: 0.25

Downside Protection: Support levels and risk management considerations are crucial due to the high volatility and beta.

Market Context & Positioning

Sector Performance: Neutral relative to the sector/market

Institutional Activity: Institutional interest is moderate, with a mix of buying and selling activity.

Correlation Analysis: The stock moves relatively strongly compared to the market (R-squared interpretation).

Relative Valuation: The stock is positioned within its trading range.

Key Levels & Action Items

Critical Price Levels: Support: $2.55 Resistance: $2.98

Breakout/Breakdown Levels: None identified

Time-Sensitive Catalysts: Earnings report and FDA approvals/product launches

Risk Management: Stop-loss levels and position sizing considerations are crucial due to the high volatility and beta.

This comprehensive analysis provides a detailed assessment of CGEN's technical, news, and risk factors. The high volatility and beta indicate a higher risk profile, making it essential to carefully evaluate potential catalysts and risks before making an investment decision.

Generated
Earnings History
7 of 7 under expected move
Avg Expected Move
95.17%
Avg Actual Move
5.98%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2025-05-19 Pre-Market 172.76% 0.00% 0.00x Within
2025-08-06 Pre-Market 73.63% 0.00% 0.00x Within
2025-11-10 Pre-Market 214.51% 3.09% 0.01x Within
2026-03-02 Pre-Market 40.06% 24.31% 0.61x Within
2026-05-18 Pre-Market 18.18% 4.00% 0.22x Within
2026-08-03 Pre-Market 15.96% 1.28% 0.08x Within
2026-11-09 Pre-Market 131.09% 9.18% 0.07x Within

Earnings calendar: this week’s reports with expected vs actual moves →

CGEN Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $0.60
7-DTE Move: $0.97
Days to Exp: 29 (2026-12-18)

Options Flow · All expiries

Call Volume: 23
Put Volume: 45
P/C Volume: 1.957
BEARISH
Call OI: 3,212
Put OI: 1,198
P/C OI: 0.373
Total OI: 4,410

ATM Options Pricing

ATM Call: $0.05
ATM Put: $0.55
Call %: 2.0%
Put %: 22.0%

Chain Summary

Chain Volume: 68
Chain OI: 4,410
Last Updated: 11/19/2026

CGEN Implied Volatility

Loading implied volatility…

The 30-day IV is the at-the-money implied volatility of options 30 days out, the blue line. The band is its 20-session average, 2 standard deviations either side. Realized volatility is how much CGEN actually moved over the last 20 sessions, from closing prices, on the same yearly scale. Without earnings takes each earnings report out of the 30-day IV, sized from what options paid for past reports, so it shows whether options are expensive or cheap apart from the report. Click a name above the chart to show or hide it.

Spread Scanner

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Scanning bull put, bear call, iron condor and calendar spreads…

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 31st percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
31%
vs own history
GEX tilt
+0.20
OI-weighted, today
Vanna tilt
+0.32
δ-sensitivity to IV
Charm tilt
-0.16
δ-decay vs time
Vanna tilt +0.32: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 3 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Put vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Call vs ATM
IV(call wing) − IV(ATM), in vol points

The same measure on the upside: how the OTM call is priced against the at-the-money strike.

  • Negative (typical) — calls trade below ATM for most stocks and indices, so the sign alone says little.
  • Percentile vs own history: high = upside calls unusually rich for this name (squeezes, takeover talk, commodity supply scares); low = calls cheaper than usual.
Reading them together

Put or call vs ATM tells you how expensive that tail is. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d put —
— pts EXTREME
No data
30 DTE / 10d put —
— pts EXTREME
No data

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Loading the implied volatility surface…

Volatility Smile

Loading the implied volatility smile…

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.60Nov 19
Beta Analysis

Risk Metrics

Beta: 1.5634
Alpha: 21.40%
Correlation: 0.3333
R-Squared: 11.1%
Stock Volatility: 64.6%
Market Volatility: 13.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own CGEN
4 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Renaissance Technologies Hedge fund
Jim Simons
$3.7M
0.01%
#1631 of 3151-17.8%13F
Millennium Management Hedge fund
Izzy Englander
$561K
0.00%
#3131 of 3716+55.1%13F
Citadel Hedge fund
Ken Griffin
$222K
0.00%
#5384 of 6285-7.9%13F
Point72 Hedge fund
Steve Cohen
$25K
0.00%
#1907 of 1945new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

CGEN Institutional Ownership (13F)

Filings for 2026-09-30
Diluted shares outstanding: 93,815,083 (as of 2025-12-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

84 filers14,314,539 shares$33.34M value15.26% of float
# Filer Shares Value % of Total % of Float Period
1 SILVERARC CAPITAL MANAGEMENT, LLC 3,586,785 $8.54M 25.61% 3.82% 2026-09-30
2 RENAISSANCE TECHNOLOGIES LLC 1,544,200 $3.68M 11.02% 1.65% 2026-09-30
3 Morgan Stanley Custodian 970,610 $2.31M 6.93% 1.03% 2026-09-30
4 NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 1,020,000 $2.18M 6.55% 1.09% 2026-06-30
5 ARK Investment Management LLC 887,867 $2.11M 6.34% 0.95% 2026-09-30
6 Taylor Frigon Capital Management LLC 816,253 $1.94M 5.83% 0.87% 2026-09-30
7 Two Sigma Investments, LP Custodian 512,419 $1.10M 3.29% 0.55% 2026-06-30
8 Altshuler Shaham Ltd 450,625 $1.07M 3.22% 0.48% 2026-09-30
9 State Street Corp 434,474 $1.03M 3.10% 0.46% 2026-09-30
10 Atom Investors LP 303,526 $649.55K 1.95% 0.32% 2026-06-30
11 Arrowstreet Capital, Limited Partnership 265,815 $632.64K 1.90% 0.28% 2026-09-30
12 UBS Group AG Custodian 263,564 $627.28K 1.88% 0.28% 2026-09-30
13 Yelin Lapidot Holdings Management Ltd. 241,983 $575.92K 1.73% 0.26% 2026-09-30
14 Millennium Management LLC Custodian 262,032 $560.75K 1.68% 0.28% 2026-06-30
15 WINTON GROUP Ltd 174,221 $414.65K 1.24% 0.19% 2026-09-30
16 American Century Companies, Inc. 158,492 $377.21K 1.13% 0.17% 2026-09-30
17 DAFNA Capital Management LLC 168,232 $360.02K 1.08% 0.18% 2026-06-30
18 ROTHSCHILD INVESTMENT LLC 141,600 $337.01K 1.01% 0.15% 2026-09-30
19 Arax Advisory Partners Custodian 131,800 $313.68K 0.94% 0.14% 2026-09-30
20 XTX Topco Ltd 119,074 $254.82K 0.76% 0.13% 2026-06-30
21 Cresset Asset Management, LLC 111,079 $237.71K 0.71% 0.12% 2026-06-30
22 Raymond James Financial, Inc. Custodian 96,068 $228.64K 0.69% 0.10% 2026-09-30
23 MATRIX ASSET ADVISORS INC/NY 93,833 $223.32K 0.67% 0.10% 2026-09-30
24 Citadel Advisors LLC Custodian 103,526 $221.55K 0.66% 0.11% 2026-06-30
25 Kingsview Wealth Management, LLC 83,179 $197.97K 0.59% 0.09% 2026-09-30
4 filers$219.38K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $108.71K 49.55% 2026-06-30
2 Citadel Advisors LLC Custodian $106.14K 48.38% 2026-06-30
3 GROUP ONE TRADING LLC Custodian $3.33K 1.52% 2026-09-30
4 Simplex Trading, LLC Custodian $1.19K 0.54% 2026-09-30
3 filers$310.11K notional
# Filer Notional Value % of Total Period
1 Susquehanna International Group, LLP Custodian $267.29K 86.19% 2026-06-30
2 Citadel Advisors LLC Custodian $42.59K 13.73% 2026-06-30
3 GROUP ONE TRADING LLC Custodian $238 0.08% 2026-09-30

CGEN Insider Trading (Form 4)

Latest: 2026-07-30
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-07-30 Sanford S Zweifach Director Award (A) +7,500 — EDGAR
2026-07-30 Anat Cohen-Dayag Director Grant (A) +100,000 opt — EDGAR
2026-07-30 David Silberman Chief Financial Officer Award (A) +19,500 — EDGAR
2026-07-30 Savitzky Kinneret Livnat Director Award (A) +7,500 — EDGAR
2026-07-30 Eran Ophir President and CEO Grant (A) +200,000 opt — EDGAR
2026-07-30 Mathias Hukkelhoven Director Award (A) +7,500 — EDGAR
2026-07-30 Pierre Ferre Chief Operating Officer Grant (A) +70,000 opt — EDGAR
2026-07-30 Eran Perry Director Award (A) +7,500 — EDGAR
2026-07-30 Zurit Levine SVP, Business Development Award (A) +18,000 — EDGAR
2026-07-30 Gilead Halevy Director Award (A) +7,500 — EDGAR
2026-07-30 Russo Sharon Kredo SVP, Research & Discovery Award (A) +18,000 — EDGAR
2026-07-30 Michelle Mahler Chief Medical Officer Award (A) +13,500 — EDGAR
2026-07-13 Zurit Levine SVP, Business Development Mixed
Sell −1,875 · Exer +1,875
— $1.66 -$3.1K EDGAR
2026-04-27 Zurit Levine SVP, Business Development Mixed
Sell −2,000 · Exer +2,000
— $2.17 -$4.1K EDGAR
2026-04-27 Eran Ophir President and CEO Mixed
Sell −5,000 · Exer +5,000
— $2.01 -$11.9K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

CGEN Insider Holdings

10 insiders · @ $1.90
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 David Silberman Chief Financial Officer 55,000 $104.5K $0 1 2026-07-30
2 Zurit Levine SVP, Business Development 47,375 $90.0K -$83.4K 9 2026-07-30
3 Russo Sharon Kredo SVP, Research & Discovery 37,500 $71.2K $0 1 2026-07-30
4 Michelle Mahler Chief Medical Officer 36,625 $69.6K $0 1 2026-07-30
5 Savitzky Kinneret Livnat Director 20,850 $39.6K $0 1 2026-07-30
6 Sanford S Zweifach Director 20,180 $38.3K $0 1 2026-07-30
7 Gilead Halevy Director 18,907 $35.9K $0 1 2026-07-30
8 Mathias Hukkelhoven Director 17,500 $33.2K $0 1 2026-07-30
9 Eran Perry Director 17,500 $33.2K $0 1 2026-07-30
10 Eran Ophir President and CEO 16,375 $31.1K -$42.9K 4 2026-07-30
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

CGEN Board & Officers

As of SEC filings through Jul 30, 2026

Directors 8

Officers 6

Changes in the last 10 years (14)
Mar 18, 2026Zurit Levine became SVP, Business Development
Mar 18, 2026Savitzky Kinneret Livnat became a director
Mar 18, 2026Sanford S Zweifach became a director
Mar 18, 2026Russo Sharon Kredo became SVP, Research & Discovery
Mar 18, 2026Pierre Ferre became Chief Operating Officer
Mar 18, 2026Michelle Mahler became Chief Medical Officer
Mar 18, 2026Michele Holcomb became a director
Mar 18, 2026Mathias Hukkelhoven became a director
Mar 18, 2026Gilead Halevy became a director
Mar 18, 2026Eran Perry became a director
Mar 18, 2026Eran Ophir became a director
Mar 18, 2026Eran Ophir became President and CEO
Mar 18, 2026David Silberman became Chief Financial Officer
Mar 18, 2026Anat Cohen-Dayag became a director
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

CGEN Proposed Insider Sales (Form 144)

Latest: 2026-04-27
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-04-27 Ophir Eran Officer 5,000 $14.6K 2026-04-24 Oppenheimer & Co. Inc 10b5-1 EDGAR
2026-04-27 Levine Zurit Officer 4,000 $11.7K 2026-04-24 Oppenheimer & Co. Inc 10b5-1 EDGAR
2026-04-15 Ophir Eran Officer 5,000 $13.8K 2026-04-14 Oppenheimer & Co. Inc 10b5-1 EDGAR
2026-04-15 Levine Zurit Officer 2,000 $5.5K 2026-04-14 Oppenheimer & Co. Inc 10b5-1 EDGAR
2026-04-13 Levine Zurit Officer 2,000 $5.0K 2026-04-10 Oppenheimer & Co. Inc 10b5-1 EDGAR
2026-04-02 Ophir Eran Officer 5,625 $12.0K 2026-04-01 Oppenheimer & Co. Inc 10b5-1 EDGAR
2026-03-26 Levine Zurit Officer 24,375 $50.2K 2026-03-26 Oppenheimer & Co. Inc 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
6 ETFs hold CGEN
6 shown · $1.19M total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 SPDW State Street® SPDR® Portfolio Developed World ex-US ETF SPDR (State Street) 0.00% $739,496 $40.7B 2026-11-17
2 AVDV Avantis International Small Cap Value ETF Avantis 0.00% $176,485 $19.3B 2026-11-17
3 GWX State Street® SPDR® S&P® International Small Cap ETF SPDR (State Street) 0.02% $158,530 $877.8M 2026-11-17
4 QQQS Invesco NASDAQ Future Gen 200 ETF Invesco 0.49% $95,496 — 2026-11-17
5 AVSD Avantis Responsible International Equity ETF Avantis 0.01% $23,759 $368.6M 2026-11-17
6 IZRL ARK Israel Innovative Technology ETF ARK Invest 1.65% — — 2026-11-18
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q4 '252025-12-31————
Q4 '242024-12-31————
Q4 '232023-12-31————
Q4 '222022-12-31————
Q4 '212021-12-31————
Q4 '202020-12-31————
Q4 '192019-12-31————
Q4 '182018-12-31————
Q4 '172017-12-31————
Q4 '162016-12-31————
Q4 '152015-12-31————
Q4 '142014-12-31————
Q4 2025 • period ending 2025-12-31 • filed 2026-03-02

CGEN vs Peers

Related companies, largest first
Company Market cap P/E Revenue growth YTD IV rank
FROG JFrog Ltd. Ordinary Shares $14.3B — +27.8% +98.9% 34
NVMI Nova Ltd. Ordinary Shares $9.9B — — −10.8% 17
NYAX Nayax Ltd. Ordinary Shares $1.9B — — −3.5% —
DRTS Alpha Tau Medical Ltd. Ordinary Shares $1.1B — — +131.5% 41
PLTK Playtika Holding Corp. Common Stock $983M — +3.7% −37.3% 19
NEXN Nexxen International Ltd. Ordinary Share $545M — — +49.1% 8
MDWD MediWound Ltd. $196M — — −25.9% 13
CGEN Compugen Ltd $186M — — +22.6% 30
TATTF TATTF — — — — —
Peer median $1.1B — +15.8% −3.5% 18

P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.

Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
2.53M
SI % of Float
2.70%
Days to Cover
9.70
Short Vol Ratio
63.9%
Free Float
93.46M
Float %
99.9%
Short interest 2026-10-30 • Short volume 2026-11-18 • Float 2026-04-15